CHFR and ovarian cancer: These results appear to be at odds with the conclusions of Zhang et al. [35], who indicated that high levels of UBC13 protein, acting through DNMT1 to suppress CHFR expression, are associated with improved response of ovarian cancer to paclitaxel-containing therapy.